显微镜下多血管炎相关间质性肺病合并COVID-19患者疫苗保护作用初探  

Study on the protective effect of vaccine in patients with microscopic polyangiitis-interstitial lung disease complicated with COVID-19 infection

作　　者：祁福敏 苏睿 郝剑 苏丽 范倩[1] 李昕[1] 魏蔚[1] QI Fumin;SU Rui;HAO Jian;SU Li;FAN Qian;LI Xin;WEI Wei(Department of Rheumatology and Immunology,Tianjin Medical University General Hospital,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院风湿免疫科,300052

出　　处：《天津医药》2024年第7期683-686,共4页Tianjin Medical Journal

摘　　要：目的分析显微镜下多血管炎(MPA)相关间质性肺病(ILD)患者合并新型冠状病毒肺炎(COVID-19)的临床特征,初步探究新型冠状病毒(SARS-CoV-2)疫苗的保护作用。方法纳入确诊的MPA-ILD患者,同时符合《新型冠状病毒感染诊疗方案(第十版)》制定的COVID-19诊断标准,且均有明确SARS-CoV-2抗原或核酸检测阳性证据。收集并分析患者临床资料,ILD影像学分型,SARS-CoV-2疫苗接种情况、临床分型及预后。结果共纳入37例MPA-ILD患者,女14例,男23例。32例在并发COVID-19时MPA病情处于缓解期,31例同时维持免疫抑制剂或生物制剂治疗。ILD的影像学类型以寻常型间质性肺炎(15例)和非特异性间质性肺炎(14例)为主,剩余8例分型不确定。COVID-19分型中,27例为轻症,5例因COVID-19死亡。11例未接种疫苗,26例接种SARS-CoV-2灭活疫苗,其中11例完成3剂次加强免疫。接种疫苗患者COVID-19轻症比例高于未接种疫苗组(P=0.038)。多因素分析显示接种疫苗为MPA-ILD患者合并COVID-19住院(OR=0.045,95%CI:0.004~0.472,P=0.010)及非轻症感染(OR=0.049,95%CI:0.005~0.517,P=0.012)的独立保护因素。同时MPA处于缓解期为COVID-19非轻症感染的保护因素(OR=0.021,95%CI:0.001~0.459,P=0.014)。结论接种SARS-CoV-2疫苗及MPA病情处于缓解期有可能减轻MPA患者合并COVID-19的严重程度。Objective To analyze the clinical features of microscopic polyangiitis(MPA)-associated interstitial lung disease(ILD)patients infected with coronavirus disease-2019(COVID-19),and investigate the protective effect of SARS-CoV-2 vaccine.Methods Patients with MPA-ILD in the General Hospital of Tianjin Medical University were included,and patients also met the diagnostic criteria for COVID-19 in accordance with the COVID-19's diagnosis and treatment plan(10th Edition).All of patients had positive evidence of coronavirus antigens or positive nucleic acid tests.Clinical data of patients,ILD imaging typing,COVID-19 vaccination,clinical typing and prognostic results were collected and analyzed.Results Thirty-seven patients with MPA-ILD were included,including 14 females and 23 males.Thirty-two patients with MPA were in remission at the time of infection with COVID-19,and 31 were maintained on concurrent immunosuppressive/biologic therapy.The original imaging type of MPA-ILD was predominantly usual interstitial pneumonia(UIP,15 cases)and nonspecific interstitial pneumonia(NSIP,14 cases).The typing of the remaining 8 cases was inconclusive.Of the COVID-19 subtypes,27 patients were mild infection,and 5 dead due to COVID-19.Eleven patients were unvaccinated,and 26 received inactivated vaccine.Among them,11 completed 3-dose of booster immunization.The proportion of patients with mild COVID-19 was significantly higher in MPA-ILD patients with vaccinated patient group than that in the unvaccinated patient group(P=0.038).Multifactorial analysis showed that vaccines were an independent protective factor for MPA-ILD patients with COVID-19 infection(OR=0.045,95%CI:0.004-0.472,P=0.010)and non-mild infection(OR=0.049,95%CI:0.005-0.517,P=0.012).Moreover,MPA in remission was a protective factor for COVID-19 non-mild infections(OR=0.021,95%CI:0.001-0.459,P=0.014).Conclusion Vaccination and MPA in remission may reduce the severity of COVID-19 infection in patients with MPA.

关 键 词：显微镜下多血管炎 新型冠状病毒肺炎 COVID-19疫苗 

分 类 号：R593.2[医药卫生—内科学]